Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lantern Pharma Inc. (LTRN)
USD3.05
-0.02 (-0.65%)
US NASDAQ Healthcare Biotechnology
Address
1920 McKinney Avenue 75201
Dallas, TX, US
Dallas, TX, US
CEO
Panna Sharma
Website
lanternpharma.com
IPO
2020-06-11
CIK 1763950 ISIN US51654W1018
Description
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.05
-0.02 (-0.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
264.2K
Beta
2.33
Float Shares
8.57M
Free Float %
75.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.32% | +49.52% | +26.10% | +14.60% | -6.55% | +3.63% | -12.53% | -35.92% | -77.01% | -79.00% | -79.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
3.05
DCF (Unlevered)
398.63
+12,969.9%
DCF (Levered)
398.63
+12,969.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-20.03
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+99.9% ★ Q1'26: +28.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +483.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.3% ★ Q1'26: +4.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.37× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
1.95M
1.95M – 1.95M
|
14.60M
14.60M – 14.60M
+648.7% YoY
|
33.80M
33.80M – 33.80M
+131.5% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-22.20M
|
-17.96M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-22.22M
|
-17.98M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-20.78M
est: -20.61M (-0.8%)
|
-17.12M
est: -18.20M (+5.9%)
|
-18.96M
-18.96M – -18.96M
-4.2% YoY
|
-22.01M
-22.01M – -22.01M
-16.1% YoY
|
-22.99M
-22.99M – -22.99M
-4.5% YoY
|
-23.98M
-23.98M – -23.98M
-4.3% YoY
|
-25.94M
-25.94M – -25.94M
-8.2% YoY
|
| SGA |
6.09M
|
6.46B
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1,930.92
est: -1.92 (-100,731.3%)
|
-1.57
est: -1.67 (+6.0%)
|
-1.74
-1.74 – -1.74
-4.2% YoY
|
-2.02
-2.02 – -2.02
-16.1% YoY
|
-2.11
-2.11 – -2.11
-4.5% YoY
|
-2.20
-2.20 – -2.20
-4.3% YoY
|
-2.38
-2.38 – -2.38
-8.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
1.07M
Insider transactions (90d)
2
Beneficial owners (>5%)
21
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AARON GLENN LOUIS FLETCHER | 1.97M | 30.60% | — | 1.97M | — | 1.97M | IN | — | 2020-06-23 | ↗ |
| 2 | BIOS ADVISORS GP, LLC | 1.97M | 30.60% | — | 1.97M | — | 1.97M | OO | — | 2020-06-23 | ↗ |
| 3 | BIOS CAPITAL MANAGEMENT, LP | 1.97M | 30.60% | — | 1.97M | — | 1.97M | PN | — | 2020-06-23 | ↗ |
| 4 | CAVU ADVISORS, LLC | 1.97M | 30.60% | — | 1.97M | — | 1.97M | OO | — | 2020-06-23 | ↗ |
| 5 | CAVU MANAGEMENT, LP | 1.97M | 30.60% | — | 1.97M | — | 1.97M | PN | — | 2020-06-23 | ↗ |
| 6 | LESLIE WAYNE KREIS, JR. | 1.97M | 30.60% | — | 1.97M | — | 1.97M | IN | — | 2020-06-23 | ↗ |
| 7 | BIOS EQUITY PARTNERS II, LP | 1.04M | 16.50% | — | 1.04M | — | 1.04M | PN | — | 2020-06-23 | ↗ |
| 8 | BIOS EQUITY PARTNERS, LP | 927.0K | 14.60% | — | 927.0K | — | 927.0K | PN | — | 2020-06-23 | ↗ |
| 9 | BIOS FUND II QP, LP | 723.6K | 11.50% | — | 723.6K | — | 723.6K | PN | — | 2020-06-23 | ↗ |
| 10 | Empery Asset Management, LP | 700.0K | 6.66% | — | 700.0K | — | — | PN | Delaware | 2021-01-25 | ↗ |
| 11 | Martin D. Hoe | 700.0K | 6.66% | — | 700.0K | — | — | IN | Delaware | 2021-01-25 | ↗ |
| 12 | Ryan M. Lane | 700.0K | 6.66% | — | 700.0K | — | — | IN | Delaware | 2021-01-25 | ↗ |
| 13 | BIOS FUND I, LP | 564.0K | 9.00% | — | 564.0K | — | 564.0K | PN | — | 2020-06-23 | ↗ |
| 14 | of 17 Pages | 525.3K | 5.00% | — | — | 525.3K | 525.3K | OO | — | 2021-02-16 | ↗ |
| 15 | s | 495.5K | 7.40% | 495.5K | — | 495.5K | — | IN | United States | 2020-06-19 | ↗ |
| 16 | Arunkumar Asaithambi | 470.5K | 4.50% | 470.5K | — | 470.5K | — | IN | India | 2021-02-16 | ↗ |
| 17 | BIOS FUND I QP, LP | 329.9K | 5.30% | — | 329.9K | — | 329.9K | PN | — | 2020-06-23 | ↗ |
| 18 | BIOS FUND II, LP | 221.5K | 3.60% | — | 221.5K | — | 221.5K | PN | — | 2020-06-23 | ↗ |
| 19 | BIOS FUND II NT, LP | 96.9K | 1.60% | — | 96.9K | — | 96.9K | PN | — | 2020-06-23 | ↗ |
| 20 | BP DIRECTORS, LP | 33.0K | 0.50% | — | 33.0K | — | 33.0K | PN | — | 2020-06-23 | ↗ |
| 21 | SCHEDULE 13D | 12.00 | 14.00% | 1.04M | — | 1.04M | — | CO | — | 2020-06-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-23 vs prev Q
New positions
3
Closed positions
25
Increased
6
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BIOS CAPITAL MANAGEMENT, LP | 1.01M -6.2K (-0.6%) | 3.06M -1.4M (-30.8%) | 9.32% -0.100 pp | 3.70% -1.267 pp | USD3.19 -5.0% | 5 qtrs — |
| 2 | VANGUARD GROUP INC | 384.0K +— (+0.0%) | 1.16M -506.9K (-30.3%) | 3.55% -0.016 pp | 0.00% +0.000 pp | USD14.73 -79.4% | 20 qtrs — |
| 3 | CM MANAGEMENT, LLC | 225.0K +— (+0.0%) | 681.8K -297.0K (-30.3%) | 2.08% -0.009 pp | 0.57% -0.241 pp | USD4.50 -32.7% | 16 qtrs — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 110.4K +10.3K (+10.3%) | 334.5K -100.9K (-23.2%) | 1.02% +0.091 pp | 0.00% 0.000 pp | USD5.74 -47.2% | 16 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 96.7K +4.7K (+5.1%) | 293.2K -107.5K (-26.8%) | 0.89% +0.039 pp | 0.00% +0.000 pp | USD11.50 -73.7% | 20 qtrs — |
| 6 | VOSS CAPITAL, LLC | 50.0K +— (+0.0%) | 151.5K -66.0K (-30.3%) | 0.46% -0.002 pp | 0.01% -0.003 pp | USD3.19 -5.0% | 5 qtrs — |
| 7 | BLACKROCK, INC. | 44.3K +1.2K (+2.7%) | 134.1K -53.4K (-28.5%) | 0.41% +0.009 pp | 0.00% +0.000 pp | USD3.64 -16.8% | 6 qtrs — |
| 8 | DIMENSIONAL FUND ADVISORS LP | 39.1K -1.0K (-2.6%) | 118.5K -56.1K (-32.1%) | 0.36% -0.011 pp | 0.00% +0.000 pp | USD3.93 -22.9% | 9 qtrs — |
| 9 | NEWEDGE ADVISORS, LLC | 38.1K -9.2K (-19.5%) | 115.4K -90.3K (-43.9%) | 0.35% -0.087 pp | 0.00% -0.001 pp | USD13.80 -78.0% | 19 qtrs — |
| 10 | WESTSIDE INVESTMENT MANAGEMENT, INC. | 35.9K +— (+0.0%) | 108.8K -47.4K (-30.3%) | 0.33% -0.002 pp | 0.02% -0.008 pp | USD3.87 -21.7% | 7 qtrs — |
| 11 | CITADEL ADVISORS LLC | 32.9K +32.9K (+100.0%) | 99.7K +99.7K (+100.0%) | 0.30% +0.304 pp | 0.00% +0.000 pp | USD3.03 +0.0% | 1 qtrs NEW |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 28.8K -10.3K (-26.3%) | 87.3K -82.7K (-48.7%) | 0.27% -0.097 pp | 0.00% +0.000 pp | USD4.35 -30.3% | 8 qtrs — |
| 13 | HORIZON KINETICS ASSET MANAGEMENT LLC | 27.6K -1.2K (-4.2%) | 83.6K -41.7K (-33.3%) | 0.25% -0.012 pp | 0.00% 0.000 pp | USD4.74 -36.1% | 12 qtrs — |
| 14 | BANK OF NEW YORK MELLON CORP | 26.5K +— (+0.0%) | 80.2K -35.0K (-30.3%) | 0.24% -0.001 pp | 0.00% +0.000 pp | USD16.16 -81.3% | 20 qtrs — |
| 15 | DAVENPORT & CO LLC | 23.8K -2.0K (-7.7%) | 72.2K -40.1K (-35.7%) | 0.22% -0.020 pp | 0.00% 0.000 pp | USD4.52 -33.0% | 7 qtrs — |
| 16 | STATE STREET CORP | 23.7K +— (+0.0%) | 71.7K -31.2K (-30.3%) | 0.22% -0.001 pp | 0.00% +0.000 pp | USD10.86 -72.1% | 18 qtrs — |
| 17 | COLONY GROUP, LLC | 16.0K +16.0K (+100.0%) | 48.4K +48.4K (+100.0%) | 0.15% +0.148 pp | 0.00% +0.000 pp | USD3.03 +0.0% | 1 qtrs NEW |
| 18 | NORTHERN TRUST CORP | 15.6K +— (+0.0%) | 47.2K -20.6K (-30.3%) | 0.14% -0.001 pp | 0.00% +0.000 pp | USD15.41 -80.3% | 20 qtrs — |
| 19 | CIBC PRIVATE WEALTH GROUP, LLC | 15.4K +15.4K (+100.0%) | 46.8K +46.8K (+100.0%) | 0.14% +0.142 pp | 0.00% +0.000 pp | USD3.03 +0.0% | 1 qtrs NEW |
| 20 | CETERA INVESTMENT ADVISERS | 12.2K +12.2K (+100.0%) | 37.1K +37.1K (+100.0%) | 0.11% +0.113 pp | 0.00% +0.000 pp | USD3.03 +0.0% | 1 qtrs NEW |
| 21 | JANE STREET GROUP, LLC | 11.7K +11.7K (+100.0%) | 35.5K +35.5K (+100.0%) | 0.11% +0.108 pp | 0.00% +0.000 pp | USD3.03 +0.0% | 1 qtrs NEW |
| 22 | UBS GROUP AG | 10.6K -22.5K (-67.9%) | 32.2K -112.0K (-77.7%) | 0.10% -0.209 pp | 0.00% +0.000 pp | USD6.88 -56.0% | 23 qtrs — |
| 23 | GROUP ONE TRADING, L.P. | 4.1K -1.0K (-19.7%) | 12.3K -9.7K (-44.1%) | 0.04% -0.009 pp | 0.00% +0.000 pp | USD3.65 -17.0% | 3 qtrs — |
| 24 | SIMPLEX TRADING, LLC | 2.3K +831.0 (+58.3%) | 6.8K +838.0 (+14.0%) | 0.02% +0.008 pp | 0.00% +0.000 pp | USD3.86 -21.5% | 2 qtrs — |
| 25 | CURIO WEALTH, LLC | 2.0K +2.0K (+100.0%) | 6.7K +6.7K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.002 pp | USD3.03 +0.0% | 5 qtrs — |
| 26 | SBI SECURITIES CO., LTD. | 2.1K +— (+0.0%) | 6.5K -2.8K (-30.3%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD3.19 -5.0% | 5 qtrs — |
| 27 | WELLS FARGO & COMPANY/MN | 1.5K -250.0 (-14.5%) | 4.5K -3.0K (-40.4%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD7.68 -60.5% | 21 qtrs — |
| 28 | TOWER RESEARCH CAPITAL LLC (TRC) | 841.00 +411.0 (+95.6%) | 2.5K +678.0 (+36.3%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD4.59 -34.0% | 23 qtrs — |
| 29 | MORGAN STANLEY | 601.00 +— (+0.0%) | 1.8K -793.0 (-30.3%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD5.12 -40.8% | 9 qtrs — |
| 30 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 500.00 +— (+0.0%) | 1.5K -660.0 (-30.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.16 -4.1% | 3 qtrs — |
| 31 | ADVISOR GROUP HOLDINGS, INC. | 215.00 +— (+0.0%) | 651.00 -284.0 (-30.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.33 -9.0% | 4 qtrs — |
| 32 | JPMORGAN CHASE & CO | 69.00 +69.0 (+100.0%) | 209.00 +209.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD3.03 +0.0% | 1 qtrs NEW |
| 33 | BANK OF AMERICA CORP /DE/ | 7.00 +1.0 (+16.7%) | 21.00 -5.0 (-19.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 -24.3% | 9 qtrs — |
| 34 | KEY FINANCIAL INC | 2.00 +— (+0.0%) | 6.00 -2.0 (-25.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 +1.0% | 3 qtrs — |
| 35 | TWO SIGMA INVESTMENTS, LP | — -16.0K (-100.0%) | — -69.8K (-100.0%) | 0.00% -0.149 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 36 | SANCTUARY ADVISORS, LLC | — -10.0K (-100.0%) | — -35.4K (-100.0%) | 0.00% -0.093 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 37 | COMMONWEALTH EQUITY SERVICES, LLC | — -18.2K (-100.0%) | — -79.0K (-100.0%) | 0.00% -0.168 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 38 | ALLWORTH FINANCIAL LP | — -2.1K (-100.0%) | — -9.1K (-100.0%) | 0.00% -0.020 pp | 0.00% +0.000 pp | USD— | 12 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 15 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Horizon Kinetics Medical ETF MEDX | 0.49% | 90.6K | 0.85% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 284.6K | 0.05% |
| 3 | Dimensional - US Sustainability Core 1 ETF DFSU | 0.00% | 6.5K | 0.15% |
| 4 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.9K | 0.03% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 386.75 | 0.17% |
| 6 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 5.2K | 0.17% |
| 7 | Vanguard Total Stock Market ETF VTI | 0.00% | 894.7K | 0.03% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.0K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.1K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 431.13 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.00
Neutral
Buys
2
Sells
2
Shares acquired
97.1K
Shares disposed
97.1K
Cash buys
4.00
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Schalop Lee Troy | Director | P-Purchase | D | Common stock purchase warrant (Right to Buy) | 48,544 | 2.27 | 110.2K | 48,544 | D | ↗ |
| 2026-05-12 | KEYSER D JEFFREY | Director | P-Purchase | A | Common stock, $0.001 par value | 48,544 | 2.06 | 100.0K | 94,303 | D | ↗ |
| 2026-01-09 | Silberstein David S. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 3.49 | 87.3K | 25,000 | D | ↗ |
| 2026-01-09 | Schalop Lee Troy | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 3.49 | 87.3K | 25,000 | D | ↗ |
| 2026-01-09 | Maccecchini Maria-Luisa | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 3.49 | 87.3K | 25,000 | D | ↗ |
| 2026-01-09 | KEYSER D JEFFREY | Director | A-Award | A | Stock Option (Right to Buy) | 28,844 | 3.49 | 100.7K | 28,844 | D | ↗ |
| 2026-01-09 | Chandru Vijay | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 3.49 | 87.3K | 25,000 | D | ↗ |
| 2025-12-18 | Margrave David R. | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.24 | 64.8K | 20,000 | D | ↗ |
| 2025-12-18 | Bhatia Kishor G. | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.24 | 32.4K | 10,000 | D | ↗ |
| 2025-08-19 | Schalop Lee Troy | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 4.46 | 22.3K | 5,000 | D | ↗ |
| 2025-07-24 | Schalop Lee Troy | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-13 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 7,206 | 3.09 | 22.3K | 189,117 | I | ↗ |
| 2025-06-13 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 14,218 | 3.09 | 43.9K | 373,178 | I | ↗ |
| 2025-06-12 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 10,925 | 3.38 | 36.9K | 196,323 | I | ↗ |
| 2025-06-12 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 10,925 | 3.38 | 36.9K | 196,323 | I | ↗ |
| 2025-06-11 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 171 | 3.40 | 581.40 | 207,248 | I | ↗ |
| 2025-06-11 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 171 | 3.40 | 581.40 | 207,248 | I | ↗ |
| 2025-06-10 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 1 | 3.40 | 3.40 | 54,791 | I | ↗ |
| 2025-06-10 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 3 | 3.40 | 10.20 | 207,419 | I | ↗ |
| 2025-05-29 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 3,639 | 3.03 | 11.0K | 207,422 | I | ↗ |
| 2025-05-29 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 961 | 3.03 | 2.9K | 54,792 | I | ↗ |
| 2025-05-28 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 714 | 2.87 | 2.0K | 55,753 | I | ↗ |
| 2025-05-28 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 4,620 | 2.87 | 13.3K | 360,851 | I | ↗ |
| 2025-05-27 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 1,000 | 3.05 | 3.1K | 56,467 | I | ↗ |
| 2025-05-27 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 7,478 | 3.05 | 22.8K | 421,808 | I | ↗ |
| 2024-07-24 | KEYSER D JEFFREY | Director | X-InTheMoney | A | Common stock | 3,832 | 3.13 | 12.0K | 0 | — | ↗ |
| 2024-07-15 | Silberstein David S. | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 4.35 | 21.8K | 5,000 | — | ↗ |
| 2024-07-15 | SHARMA PANNA | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 4.35 | 304.5K | 70,000 | — | ↗ |
| 2024-07-15 | Margrave David R. | Officer | A-Award | A | Stock Option (Right to Buy) | 52,000 | 4.35 | 226.2K | 52,000 | — | ↗ |
| 2024-07-15 | Maccecchini Maria-Luisa | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 4.35 | 21.8K | 5,000 | — | ↗ |
| 2024-07-15 | KEYSER D JEFFREY | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 4.35 | 21.8K | 5,000 | — | ↗ |
| 2024-07-15 | Chandru Vijay | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 4.35 | 21.8K | 5,000 | — | ↗ |
| 2024-07-15 | Bhatia Kishor G. | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 4.35 | 152.3K | 35,000 | — | ↗ |
| 2024-05-24 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 13,888 | 6.33 | 87.9K | 429,286 | — | ↗ |
| 2024-05-24 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 13,888 | 6.33 | 87.9K | 429,286 | — | ↗ |
| 2024-05-23 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 2,126 | 6.25 | 13.3K | 135,706 | — | ↗ |
| 2024-05-23 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 930 | 6.25 | 5.8K | 59,326 | — | ↗ |
| 2024-02-29 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 4,185 | 4.87 | 20.4K | 137,832 | — | ↗ |
| 2024-02-29 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 13,686 | 4.87 | 66.7K | 450,118 | — | ↗ |
| 2024-02-28 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 51,608 | 4.85 | 250.3K | 463,804 | — | ↗ |
| 2024-02-28 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 15,780 | 4.85 | 76.5K | 142,017 | — | ↗ |
| 2024-02-27 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 4,649 | 4.40 | 20.5K | 68,997 | — | ↗ |
| 2024-02-27 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 4,649 | 4.40 | 20.5K | 68,997 | — | ↗ |
| 2024-01-17 | Kreis Leslie W. | 10% Owner | X-InTheMoney | A | Common Stock | 54,873 | 3.13 | 171.8K | 591,036 | — | ↗ |
| 2024-01-17 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 5,475 | 4.20 | 23.0K | 73,646 | — | ↗ |
| 2023-11-29 | Kreis Leslie W. | 10% Owner | S-Sale | D | Common Stock | 91,708 | 3.44 | 315.5K | 371,950 | — | ↗ |
| 2023-11-29 | Fletcher Aaron G.L. | 10% Owner | S-Sale | D | Common Stock | 91,708 | 3.44 | 315.5K | 371,950 | — | ↗ |
| 2022-11-08 | Kreis Leslie W. | Director | S-Sale | D | Common Stock | 17,748 | 4.40 | 78.1K | 71,774 | — | ↗ |
| 2022-11-08 | Fletcher Aaron G.L. | Director | S-Sale | D | Common Stock | 17,748 | 4.40 | 78.1K | 71,774 | — | ↗ |
| 2022-10-20 | Maccecchini Maria-Luisa | Director | A-Award | A | Stock Option (Right to Buy) | 3,200 | 0.00 | — | 3,200 | — | ↗ |
| 2022-09-02 | Kreis Leslie W. | 10% Owner | X-InTheMoney | A | Stock Option | 6,438 | 1.03 | 6.6K | 0 | — | ↗ |
| 2022-09-02 | Fletcher Aaron G.L. | 10% Owner | X-InTheMoney | A | Stock Option | 6,438 | 1.03 | 6.6K | 0 | — | ↗ |
| 2022-09-02 | BP Directors, LP | Director | X-InTheMoney | A | Stock Option | 26,100 | 0.00 | — | 6,438 | — | ↗ |
| 2022-09-02 | BIOS Advisors GP, LLC | Director | X-InTheMoney | A | Stock Option | 26,100 | 0.00 | — | 6,438 | — | ↗ |
| 2022-08-06 | SHARMA PANNA | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-08 | Maccecchini Maria-Luisa | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-17 | Kreis Leslie W. | Director / 10% Owner | X-InTheMoney | A | Common Stock | 60,432 | 189,152.16 | 11.43B | 564,038 | — | ↗ |
| 2022-03-17 | BIOS Fund I QP, LP | Director | X-InTheMoney | D | Series A Warrants | 35,347 | 0.00 | — | 0 | — | ↗ |
| 2021-11-04 | Silberstein David S. | Director | D-Return | D | Stock Option (Right to Buy) | 3,200 | 10.32 | 33.0K | 0 | D | ↗ |
| 2021-11-04 | PRENDERGAST FRANKLYN G | Director | A-Award | A | Stock Option (Right to Buy) | 3,200 | 10.32 | 33.0K | 3,200 | — | ↗ |
| 2021-11-04 | Kreis Leslie W. | Director / 10% Owner | A-Award | A | Stock Option | 3,200 | 10.32 | 33.0K | 3,200 | — | ↗ |
| 2021-11-04 | KEYSER D JEFFREY | Director | D-Return | D | Stock Option (Right to Buy) | 3,200 | 10.32 | 33.0K | 0 | D | ↗ |
| 2021-11-04 | Chandru Vijay | Director | A-Award | A | Stock Option (Right to Buy) | 3,200 | 5.04 | 16.1K | 3,200 | D | ↗ |
| 2021-10-29 | Margrave David R. | Officer | D-Return | D | Stock Option (Right to Buy) | 26,100 | 10.21 | 266.5K | 0 | D | ↗ |
| 2021-10-29 | Bhatia Kishor G. | Officer | A-Award | A | Stock Option (Right to Buy) | 17,400 | 10.21 | 177.7K | 17,400 | — | ↗ |
| 2021-01-14 | Green Park & Golf Ventures II, LLC | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-16 | Green Park & Golf Ventures II, LLC | 10% Owner | C-Conversion | D | Series A Preferred Stock, par value $0.01 | 75,688 | 0.00 | — | 0 | — | ↗ |
| 2020-06-15 | Silberstein David S. | Director | D-Return | D | Stock Option (Right to Buy) | 9,135 | 15.00 | 137.0K | 0 | D | ↗ |
| 2020-06-15 | SHARMA PANNA | Director / Officer | D-Return | D | Stock Option (Right to Buy) | 76,628 | 15.00 | 1.15M | 0 | D | ↗ |
| 2020-06-15 | PRENDERGAST FRANKLYN G | Director | A-Award | A | Stock Option | 9,135 | 15.00 | 137.0K | 9,135 | — | ↗ |
| 2020-06-15 | Margrave David R. | Officer | A-Award | A | Stock Option (Right to Buy) | 78,300 | 5.04 | 394.6K | 78,300 | D | ↗ |
| 2020-06-15 | Kreis Leslie W. | Director / 10% Owner | A-Award | A | Stock Options | 9,135 | 15.00 | 137.0K | 9,135 | — | ↗ |
| 2020-06-15 | KEYSER D JEFFREY | Director | C-Conversion | D | Series A Preferred Stock | 18,349 | 0.00 | — | 0 | — | ↗ |
| 2020-06-15 | Green Park & Golf Ventures II, LLC | 10% Owner | C-Conversion | A | Common Stock, par value $0.0001 | 131,697 | 0.00 | — | 131,697 | — | ↗ |
| 2020-06-15 | Fletcher Aaron G.L. | 10% Owner | C-Conversion | A | Common Stock | 503,606 | 0.00 | — | 503,606 | — | ↗ |
| 2020-06-15 | Chandru Vijay | Director | A-Award | A | Stock Option (Right to Buy) | 9,135 | 5.04 | 46.0K | 9,135 | D | ↗ |
| 2020-06-15 | Bhatia Kishor G. | Officer | D-Return | D | Stock Option (Right to Buy) | 52,200 | 15.00 | 783.0K | 0 | D | ↗ |
| 2020-06-15 | Asaithambi Arunkumar | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-11 | KEYSER D JEFFREY | Director | P-Purchase | A | Common Stock | 10,000 | 15.00 | 150.0K | 10,000 | — | ↗ |
| 2020-06-10 | Silberstein David S. | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,044,000 | — | ↗ |
| 2020-06-10 | SHARMA PANNA | Director / Officer | — | D | Stock Options | 418,858 | 1.03 | 431.4K | 0 | — | ↗ |
| 2020-06-10 | PRENDERGAST FRANKLYN G | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-10 | Margrave David R. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-10 | Kreis Leslie W. | Director / 10% Owner | — | I | Series A Preferred Stock | 61,214 | 0.00 | — | 0 | — | ↗ |
| 2020-06-10 | KEYSER D JEFFREY | Director | — | D | Stock Options | 32,538 | 1.03 | 33.5K | 0 | — | ↗ |
| 2020-06-10 | Green Park & Golf Ventures II, LLC | 10% Owner | — | I | Series A Preferred Stock Warrant (right to buy) | 15,804 | 5.45 | 86.1K | 0 | — | ↗ |
| 2020-06-10 | Fletcher Aaron G.L. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 211,456 | — | ↗ |
| 2020-06-10 | Chandru Vijay | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-10 | Bhatia Kishor G. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-10 | BIOLOGICAL MIMETICS INC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,044,000 | — | ↗ |
| 2020-06-10 | Asaithambi Arunkumar | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 441,960 | — | ↗ |
| 2019-05-25 | KEYSER D JEFFREY | Director | — | D | Series A Warrants | 3,831 | 3.13 | 12.0K | 0 | — | ↗ |
| 2019-03-07 | Kreis Leslie W. | Director / 10% Owner | — | I | Series A Warrants | 7,346 | 3.13 | 23.0K | 0 | — | ↗ |
| 2019-03-07 | Fletcher Aaron G.L. | 10% Owner | — | I | Series A Warrants | 7,346 | 3.13 | 23.0K | 0 | — | ↗ |
| 2018-12-17 | Kreis Leslie W. | Director / 10% Owner | — | I | Stock Options | 32,538 | 1.03 | 33.5K | 0 | — | ↗ |
| 2018-12-17 | Fletcher Aaron G.L. | 10% Owner | — | I | Stock Options | 32,538 | 1.03 | 33.5K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
11.30M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Panna Sharma, Chief Executive Officer and President | 575.0K | 281.8K | — | 223.5K | — | 10.4K | 1.09M | 20.50% | ↗ |
| 2 | 2024 | David R. Margrave, Chief Financial Officer and Secretary | 413.8K | 162.3K | — | 166.4K | — | 10.4K | 752.9K | 22.11% | ↗ |
| 3 | 2024 | Kishor Bhatia, Ph.D., Chief Scientific Officer | 316.0K | 101.1K | — | 111.7K | — | 10.4K | 539.1K | 20.71% | ↗ |
| 4 | 2023 | Panna Sharma, Chief Executive Officer and President | 525.3K | 149.2K | — | — | — | 9.9K | 684.4K | 0.00% | ↗ |
| 5 | 2023 | David R. Margrave, Chief Financial Officer and Secretary | 353.3K | 79.5K | — | — | — | 9.9K | 442.7K | 0.00% | ↗ |
| 6 | 2023 | Kishor Bhatia, Ph.D., Chief Scientific Officer | 235.0K | 39.4K | — | — | — | 8.9K | 283.2K | 0.00% | ↗ |
| 7 | 2022 | Panna Sharma, Chief Executive Officer and President | 474.6K | 158.7K | — | 420.6K | — | — | 1.05M | 39.91% | ↗ |
| 8 | 2022 | David R. Margrave, Chief Financial Officer and Secretary | 332.7K | 61.7K | — | — | — | — | 394.4K | 0.00% | ↗ |
| 9 | 2022 | Kishor Bhatia, Ph.D., Chief Scientific Officer | 162.9K | 21.4K | — | — | — | — | 184.3K | 0.00% | ↗ |
| 10 | 2021 | Panna Sharma, Chief Executive Officer and President | 432.0K | 190.0K | — | — | — | — | 622.0K | 0.00% | ↗ |
| 11 | 2021 | David R. Margrave, Chief Financial Officer and Secretary | 300.0K | 66.0K | — | 195.3K | — | — | 561.3K | 34.80% | ↗ |
| 12 | 2021 | Kishor Bhatia, Ph.D., Chief Scientific Officer | 127.9K | 24.0K | — | 130.2K | — | — | 282.1K | 46.15% | ↗ |
| 13 | 2020 | Panna Sharma, Chief Executive Officer, and President | 384.5K | 366.0K | — | 843.7K | — | — | 1.59M | 52.92% | ↗ |
| 14 | 2020 | Panna Sharma, Chief Executive Officer and President | 384.5K | 366.0K | — | 843.7K | — | — | 1.59M | 52.92% | ↗ |
| 15 | 2020 | David R. Margrave, Chief Financial Officer and Secretary | 225.2K | 73.7K | — | 862.1K | — | — | 1.16M | 74.26% | ↗ |
| 16 | 2020 | Kishor Bhatia, Ph.D., Chief Scientific Officer | 82.4K | 10.5K | — | 574.7K | — | — | 667.6K | 86.09% | ↗ |
| 17 | 2019 | Panna Sharma, Chief Executive Officer, and President | 266.9K | 65.0K | — | — | — | — | 331.9K | 0.00% | ↗ |
| 18 | 2019 | David R. Margrave, Chief Financial Officer and Secretary | 97.0K | — | — | — | — | — | 97.0K | 0.00% | ↗ |
| 19 | 2019 | Kishor Bhatia, Ph.D., Chief Scientific Officer | 36.9K | — | — | — | — | — | 36.9K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Panna Sharma | President, Chief Executive Officer & Director | 763.8K | male |
| David R. Margrave | Chief Financial Officer & Secretary | 540.8K | male |
| Kishor Gopaldas Bhatia | Chief Scientific Officer & Scientific Consultant | 222.0K | — |
| Ernest Kitt | Head of Clinical Operations | — | male |
| Marc C. Chamberlain | Chief Medical Officer of Starlight Therapeutics | — | — |
| Peter L. Nara | Co-Founder & Advisor | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LTRN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
